| Literature DB >> 33172187 |
Yan-He Li1,2,3, Xiao-Ming Li1,2,4, Xin Li1,2,4, Sui-Qun Yang1,2,4, Xiao-Shan Shi1,2,4, Hong-Lei Li1,2,4, Bin-Gui Wang1,2,3,4.
Abstract
Nine secondary metabolites (1-9), including two new polyketide derivatives 9-dehydroxysargassopenilline A (4) and 1,2-didehydropeaurantiogriseol E (5), along with seven known related secondary metabolites (1-3 and 6-9), were isolated and identified from the deep sea-derived fungus Penicillium cyclopium SD-413. Their structures were elucidated on the basis of 1D/2D NMR spectroscopic and mass spectrometric analysis and the absolute configurations were determined by the combination of NOESY correlations and time-dependent density functional (TDDFT) ECD calculations. Compounds 1-9 inhibited some pathogenic bacteria including Escherichia coli, E. ictaluri, Edwardsiella tarda, Micrococcus luteus, Vibrio anguillarum, and V. harveyi, with MIC (minimum inhibitory concentration) values ranging from 4 to 32 μg/mL.Entities:
Keywords: Penicillium cyclopium; antibacterial activity; marine sediment-derived fungus; polyketide derivatives; quinazoline alkaloid
Mesh:
Substances:
Year: 2020 PMID: 33172187 PMCID: PMC7695020 DOI: 10.3390/md18110553
Source DB: PubMed Journal: Mar Drugs ISSN: 1660-3397 Impact factor: 5.118
Figure 1Structures of compounds 1–9.
1H and 13C NMR data of compounds 4 and 5 (measured in DMSO-d6).
| No. | 4 | No. | 5 | ||
|---|---|---|---|---|---|
| 1 | 4.34, d (14.7) | 58.2, CH2 | 1 | 7.26, d (5.9) | 157.9, CH |
| 1 | 4.49, d (14.7) | 2 | 5.19, d (5.9) | 105.6, CH | |
| 3 | 95.7, C | 3 | 199.0, C | ||
| 4 | 4.09, d (8.5) | 69.6, CH | 4 | 47.4, C | |
| 4a | 133.8, C | 5 | 1.59, m | 42.2, CH | |
| 5 | 6.55, s | 104.4, CH | 6 | 1.13, m | 26.4, CH2 |
| 6 | 154.3, C | 6 | 2.75, m | ||
| 7 | 108.9, C | 7 | 1.00, m | 29.4, CH2 | |
| 8 | 149.7, C | 7 | 1.77, m | ||
| 8a | 112.6, C | 8 | 1.48, m | 40.7, CH | |
| 9 | 1.40, m | 29.4, CH2 | 9 | 0.81, m | 35.0, CH2 |
| 9 | 1.94, m | 9 | 1.85, m | ||
| 10 | 1.61, m | 18.5, CH2 | 10 | 1.89, m | 40.1, CH |
| 10 | 1.80, m | 11 | 5.48, dd (10.1, 2.1) | 131.4, CH | |
| 11 | 1.11, m | 31.9, CH2 | 12 | 5.67, dd (10.1, 2.1) | 128.3, CH |
| 11 | 1.55, m | 13 | 85.3, C | ||
| 12 | 3.75, m | 66.9, CH | 14 | 1.37, s | 21.6, CH3 |
| 14 | 1.01, d (6.3) | 21.6, CH3 | 15 | 1.15, s | 13.9, CH3 |
| 15 | 1.95, s | 8.6, CH3 | 16 | 3.22, m | 66.3, CH2 |
| 4-OH | 4.57, d (8.5) | 16-OH | 4.42, br | ||
| 6-OH | 8.93, s | ||||
| 8-OH | 8.08, s | ||||
a Measured at 500 MHz; b measured at 125 MHz.
Figure 2Key COSY (bold lines) and HMBC (arrows) correlations of compounds 1, 4, and 5.
Figure 3Key NOESY correlations for 1, 2, 4, and 5 (solid lines: β-orientation; dashed lines: α-orientation).
Figure 4Experimental and calculated ECD spectra of compounds 4 and 5.
Antibacterial activities of compounds 1–9 (MIC, μg/mL).
| Strains | 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | Chl a |
|---|---|---|---|---|---|---|---|---|---|---|
|
| 8.0 | 4.0 | 8.0 | n.a. | 16 | 8.0 | n.a. | 32 | 16 | 2.0 |
|
| 8.0 | 8.0 | 8.0 | 16 | n.a. | 32 | 16 | 32 | 8.0 | 2.0 |
|
| 8.0 | 8.0 | 8.0 | n.a. | n.a. | n.a. | 32 | 16 | n.a. | 0.5 |
|
| 32 | n.a. | n.a. | 4.0 | 32 | n.a. | 32 | n.a. | n.a. | 2.0 |
|
| 8.0 | 8.0 | 32 | n.a. | 4.0 | 8.0 | n.a. | 32 | 32 | 0.5 |
|
| n.a. | n.a. | n.a. | 32 | 4.0 | 32 | 16 | 32 | n.a. | 1.0 |
a Chl: chloramphenicol (positive control); n.a.: no activity (MIC > 64 μg/mL).